Validation of a Genetic Risk Score Combined With Clinical Variables for Predicting Pulmonary Fibrosis in Early Rheumatoid Arthritis
Performance · Discrimination of RA-PFResult — go to the resultOdds ratio 2.6 95% CI 1.6–4.5Authors' conclusion
This study provides external validation of the Veterans Affairs Rheumatoid Arthritis Registry interstitial lung disease GRS (VARA-ILD-GRS) and the VARA-ILD-CRS in an RA cohort, demonstrating their generalizability and effectiveness in identifying individuals at high risk for RA-ILD.
Study context
- Population
- Inception cohort of patients diagnosed with early rheumatoid arthritis (RA), northern Sweden, 1996–20161,115 with complete data
- Participants
- 1,118 participants
- Comparison
- Combined risk score (CRS) vs genetic risk score (GRS) alone for predicting RA-associated pulmonary fibrosis (PF)
- Outcome
- Prediction of RA-associated PF development (GRS and CRS performance)
Methodological detailsinception cohort, logistic regression, AUC assessment
- Inception cohort
- Logistic regression
- AUC assessment
Performance
Discrimination of RA-PF
Odds ratio
2.6
95% CI 1.6–4.5
By group
CRS
0.75
AUC
GRS
0.62
AUC
GRS
OR 2.6 (95% CI 1.6–4.5)
As reported in the abstract
Further findings
RA-PF incidence among patients with complete data
- Patients with complete data diagnosed with PF
- 60 (5.6%)
- 1,115 patients with complete data
Factors associated with PF
- PF significantly associated with age, RF positivity, disease activity, and MUC5B (rs35705950) and FAM13A (rs2609255) single-nucleotide polymorphisms (SNPs)
Original publication
Validation of a Genetic Risk Score Combined With Clinical Variables for Predicting Pulmonary Fibrosis in Early Rheumatoid Arthritis. Arthritis Care Res (Hoboken). Published 1 February 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →